NCT00329719 arm group d39d7f96f73242903d27b4344a0d0bb2 [clinicaltrials_resource:NCT00329719/arm-group/d39d7f96f73242903d27b4344a0d0bb2]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00329719 arm group d39d7f96f73242903d27b4344a0d0bb2 [clinicaltrials_resource:NCT00329719/arm-group/d39d7f96f73242903d27b4344a0d0bb2]
Bio2RDF identifier
NCT00329719/arm-group/d39d7f96f73242903d27b4344a0d0bb2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 9d7f96f73242903d27b4344a0d0bb2
description [clinicaltrials_vocabulary:description]
Phase I, Arm A, Dose Escalatio ...... rience dose-limiting toxicity.
identifier
clinicaltrials_resource:NCT00329719/arm-group/d39d7f96f73242903d27b4344a0d0bb2
title
NCT00329719 arm group d39d7f96f73242903d27b4344a0d0bb2
@en
type
label
NCT00329719 arm group d39d7f96 ...... d7f96f73242903d27b4344a0d0bb2]
@en